Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Recent studies from University of Turin add new data to breast cancer
July 31st, 2008
According to recent research published in the Journal of Translational Medicine, "Trastuzumab is a monoclonal antibody selectively directed against Her2 and approved for the treatment of Her2 overexpressing breast cancer patients. Its proposed mechanisms of action include mediation of antibody-dependent cellular cytotoxicity (ADCC) by triggering Fc gamma RIII on natural killer (NK) cells." "This study addresses the correlation between overall NK function and trastuzumab's clinical activity. Clinical and immunological responses were assessed in 26 patients receiving trastuzumab monotherapy as maintenance management after chemotherapy (8 mg/kg load and then...
Source: Women's Health Weekly (2008-07-31)
|
